Liver Cancer Drugs Market size to grow by USD 5.29 billion | Market Research Insights highlight the increasing incidence of liver cancer as Key Driver | Technavio

NEW YORK, June 20, 2022 /PRNewswire/ — According to the research report “Liver Cancer Drugs Market by Type and Geography – Forecast and Analysis 2022-2026“, the market will witness a YOY growth of 10.4% at a CAGR of 14.67% during the forecast period. The report is segmented by type (immunotherapy and targeted therapy) and geography (North America, Europe, Asia, and Rest of World (ROW)).

For more insights on YOY and CAGR, Read Sample Report

Vendor Insights 
Global Liver Cancer Drugs Market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. 

The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Some vendors are also adopting inorganic growth strategies such as M&As to remain competitive in the market.   

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

  • Alnylam Pharmaceuticals Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • Eureka Therapeutics
  • Exelixis Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Lion TCR Pte. Ltd
  • Merck and Co. Inc.
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Q BioMed Inc.

Find additional highlights on the growth strategies adopted by vendors and their product offerings, Read Sample Report.

Geographical Market Analysis 
North America will account for 42% of market growth. US and Canada are the key markets for liver cancer drugs in North America. Compared to the markets in Europe and Asia, this region’s market will grow more slowly.

Over the forecast period, the expansion of the liver cancer medications market in North America would be aided by the development and introduction of treatment regimens for the disease.

Furthermore, countries such as the US, Canada, Germany, UK, and China are expected to emerge as prominent markets for Liver Cancer Drugs Market during the forecast period. 

Know more about this market’s geographical distribution along with a detailed analysis of the top regions. Click Here for Sample Report.

Competitive Analysis
The competitive scenario provided in the liver cancer drugs market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.

Market Segmentation

  • By Type, the market is classified as immunotherapy and targeted therapy.
  • By Geography, the market is classified as North America, Europe, Asia, and the Rest of the World (ROW). 

To know about the market contribution of each segment – Get the latest sample report now!

Key Market Drivers & Challenges: 
Factors such as the increasing incidence of liver cancer, and advancements in diagnostic methods will be crucial in driving the growth of the market. But factors such as the only curative option available is surgical resection and transplantation will restrict the market growth. The holistic analysis of the drivers & challenges will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Get a Sample for highlights on market Drivers & Challenges affecting Liver Cancer Drugs Market. 

Customize Your Report 
Don’t miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.  

Do reach out to our analysts for more customized reports as per your requirements. Speak to an Analyst now!     

Related Reports: 
Rare Hemophilia Factors Market by Method and Geography – Forecast and Analysis 2022-2026
Obsessive-Compulsive Disorder Drugs Market by Product and Geography – Forecast and Analysis 2022-2026

 

Liver Cancer Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 14.67%

Market growth 2022-2026

$ 5.29 billion

Market structure

Fragmented

YoY growth (%)

10.4

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Q BioMed Inc

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized

 

Table of Contents

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
    • Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ million)
    • Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ million)
    • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
    • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
    • Exhibit 17: Five forces analysis – Comparison between 2021 and 2026
  • 4.2 Bargaining power of buyers
    • Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
  • 4.3 Bargaining power of suppliers
    • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
    • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
    • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
    • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
  • 4.7 Market condition
    • Exhibit 23: Chart on Market condition – Five forces 2021 and 2026

5 Market Segmentation by Type

  • 5.1 Market segments
    • Exhibit 24: Chart on Type – Market share 2021-2026 (%)
    • Exhibit 25: Data Table on Type – Market share 2021-2026 (%)
  • 5.2 Comparison by Type
    • Exhibit 26: Chart on Comparison by Type
    • Exhibit 27: Data Table on Comparison by Type
  • 5.3 Immunotherapy – Market size and forecast 2021-2026
    • Exhibit 28: Chart on Immunotherapy – Market size and forecast 2021-2026 ($ million)
    • Exhibit 29: Data Table on Immunotherapy – Market size and forecast 2021-2026 ($ million)
    • Exhibit 30: Chart on Immunotherapy – Year-over-year growth 2021-2026 (%)
    • Exhibit 31: Data Table on Immunotherapy – Year-over-year growth 2021-2026 (%)
  • 5.4 Targeted therapy – Market size and forecast 2021-2026
    • Exhibit 32: Chart on Targeted therapy – Market size and forecast 2021-2026 ($ million)
    • Exhibit 33: Data Table on Targeted therapy – Market size and forecast 2021-2026 ($ million)
    • Exhibit 34: Chart on Targeted therapy – Year-over-year growth 2021-2026 (%)
    • Exhibit 35: Data Table on Targeted therapy – Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Type
    • Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview
    • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation
    • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
    • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
  • 7.2 Geographic comparison
    • Exhibit 40: Chart on Geographic comparison
    • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America – Market size and forecast 2021-2026
    • Exhibit 42: Chart on North America – Market size and forecast 2021-2026 ($ million)
    • Exhibit 43: Data Table on North America – Market size and forecast 2021-2026 ($ million)
    • Exhibit 44: Chart on North America – Year-over-year growth 2021-2026 (%)
    • Exhibit 45: Data Table on North America – Year-over-year growth 2021-2026 (%)
  • 7.4 Europe – Market size and forecast 2021-2026
    • Exhibit 46: Chart on Europe – Market size and forecast 2021-2026 ($ million)
    • Exhibit 47: Data Table on Europe – Market size and forecast 2021-2026 ($ million)
    • Exhibit 48: Chart on Europe – Year-over-year growth 2021-2026 (%)
    • Exhibit 49: Data Table on Europe – Year-over-year growth 2021-2026 (%)
  • 7.5 Asia – Market size and forecast 2021-2026
    • Exhibit 50: Chart on Asia – Market size and forecast 2021-2026 ($ million)
    • Exhibit 51: Data Table on Asia – Market size and forecast 2021-2026 ($ million)
    • Exhibit 52: Chart on Asia – Year-over-year growth 2021-2026 (%)
    • Exhibit 53: Data Table on Asia – Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) – Market size and forecast 2021-2026
    • Exhibit 54: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
    • Exhibit 55: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
    • Exhibit 56: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
    • Exhibit 57: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
  • 7.7 US – Market size and forecast 2021-2026
    • Exhibit 58: Chart on US – Market size and forecast 2021-2026 ($ million)
    • Exhibit 59: Data Table on US – Market size and forecast 2021-2026 ($ million)
    • Exhibit 60: Chart on US – Year-over-year growth 2021-2026 (%)
    • Exhibit 61: Data Table on US – Year-over-year growth 2021-2026 (%)
  • 7.8 Germany – Market size and forecast 2021-2026
    • Exhibit 62: Chart on Germany – Market size and forecast 2021-2026 ($ million)
    • Exhibit 63: Data Table on Germany – Market size and forecast 2021-2026 ($ million)
    • Exhibit 64: Chart on Germany – Year-over-year growth 2021-2026 (%)
    • Exhibit 65: Data Table on Germany – Year-over-year growth 2021-2026 (%)
  • 7.9 China – Market size and forecast 2021-2026
    • Exhibit 66: Chart on China – Market size and forecast 2021-2026 ($ million)
    • Exhibit 67: Data Table on China – Market size and forecast 2021-2026 ($ million)
    • Exhibit 68: Chart on China – Year-over-year growth 2021-2026 (%)
    • Exhibit 69: Data Table on China – Year-over-year growth 2021-2026 (%)
  • 7.10 Canada – Market size and forecast 2021-2026
    • Exhibit 70: Chart on Canada – Market size and forecast 2021-2026 ($ million)
    • Exhibit 71: Data Table on Canada – Market size and forecast 2021-2026 ($ million)
    • Exhibit 72: Chart on Canada – Year-over-year growth 2021-2026 (%)
    • Exhibit 73: Data Table on Canada – Year-over-year growth 2021-2026 (%)
  • 7.11 UK – Market size and forecast 2021-2026
    • Exhibit 74: Chart on UK – Market size and forecast 2021-2026 ($ million)
    • Exhibit 75: Data Table on UK – Market size and forecast 2021-2026 ($ million)
    • Exhibit 76: Chart on UK – Year-over-year growth 2021-2026 (%)
    • Exhibit 77: Data Table on UK – Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity by geography
    • Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
    • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape
    • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
    • Exhibit 81: Overview on factors of disruption
  • 9.4 Industry risks
    • Exhibit 82: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered
    • Exhibit 83: Vendors covered
  • 10.2 Market positioning of vendors
    • Exhibit 84: Matrix on vendor position and classification
  • 10.3 AstraZeneca Plc
    • Exhibit 85: AstraZeneca Plc – Overview
    • Exhibit 86: AstraZeneca Plc – Product / Service
    • Exhibit 87: AstraZeneca Plc – Key news
    • Exhibit 88: AstraZeneca Plc – Key offerings
  • 10.4 Bayer AG
    • Exhibit 89: Bayer AG – Overview
    • Exhibit 90: Bayer AG – Business segments
    • Exhibit 91: Bayer AG – Key news
    • Exhibit 92: Bayer AG – Key offerings
    • Exhibit 93: Bayer AG – Segment focus
  • 10.5 Bristol-Myers Squibb Co.
    • Exhibit 94: Bristol-Myers Squibb Co. – Overview
    • Exhibit 95: Bristol-Myers Squibb Co. – Product / Service
    • Exhibit 96: Bristol-Myers Squibb Co. – Key offerings
  • 10.6 Eisai Co. Ltd.
    • Exhibit 97: Eisai Co. Ltd. – Overview
    • Exhibit 98: Eisai Co. Ltd. – Business segments
    • Exhibit 99: Eisai Co. Ltd. – Key offerings
    • Exhibit 100: Eisai Co. Ltd. – Segment focus
  • 10.7 Eli Lilly and Co.
    • Exhibit 101: Eli Lilly and Co. – Overview
    • Exhibit 102: Eli Lilly and Co. – Business segments
    • Exhibit 103: Eli Lilly and Co. – Key offerings
    • Exhibit 104: Eli Lilly and Co. – Segment focus
  • 10.8 Eureka Therapeutics
    • Exhibit 105: Eureka Therapeutics – Overview
    • Exhibit 106: Eureka Therapeutics – Product / Service
    • Exhibit 107: Eureka Therapeutics – Key offerings
  • 10.9 Gilead Sciences Inc.
    • Exhibit 108: Gilead Sciences Inc. – Overview
    • Exhibit 109: Gilead Sciences Inc. – Business segments
    • Exhibit 110: Gilead Sciences Inc. – Key news
    • Exhibit 111: Gilead Sciences Inc. – Key offerings
    • Exhibit 112: Gilead Sciences Inc. – Segment focus
  • 10.10 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
    • Exhibit 113: Jiangsu Hengrui Pharmaceuticals Co. Ltd. – Overview
    • Exhibit 114: Jiangsu Hengrui Pharmaceuticals Co. Ltd. – Product / Service
    • Exhibit 115: Jiangsu Hengrui Pharmaceuticals Co. Ltd. – Key offerings
  • 10.11 Lion TCR Pte. Ltd
    • Exhibit 116: Lion TCR Pte. Ltd – Overview
    • Exhibit 117: Lion TCR Pte. Ltd – Product / Service
    • Exhibit 118: Lion TCR Pte. Ltd – Key offerings
  • 10.12 Merck and Co. Inc.
    • Exhibit 119: Merck and Co. Inc. – Overview
    • Exhibit 120: Merck and Co. Inc. – Business segments
    • Exhibit 121: Merck and Co. Inc. – Key news
    • Exhibit 122: Merck and Co. Inc. – Key offerings
    • Exhibit 123: Merck and Co. Inc. – Segment focus

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
    • Exhibit 124: Inclusions checklist
    • Exhibit 125: Exclusions checklist
  • 11.3 Currency conversion rates for US$
    • Exhibit 126: Currency conversion rates for US$
  • 11.4 Research methodology
    • Exhibit 127: Research methodology
    • Exhibit 128: Validation techniques employed for market sizing
    • Exhibit 129: Information sources
  • 11.5 List of abbreviations
    • Exhibit 130: List of abbreviations

About Us: 
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. 

Contact 
Technavio Research 
Jesse Maida 
Media & Marketing Executive 
US: +1 844 364 1100 
UK: +44 203 893 3200 
Email: [email protected] 
Website: www.technavio.com/ 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/liver-cancer-drugs-market-size-to-grow-by-usd-5-29-billion–market-research-insights-highlight-the-increasing-incidence-of-liver-cancer-as-key-driver–technavio-301570813.html

SOURCE Technavio

Liver Cancer Drugs Market size to grow by USD 5.29 billion | Market Research Insights highlight the increasing incidence of liver cancer as Key Driver | Technavio WeeklyReviewer

PR Newswire Science News

World Reviewer Staff
World Reviewer Staffhttps://weeklyreviewer.com/
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

Related articles